CIK 0001869105 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BridgeBio Oncology Therapeutics, Inc.
Sign in to watch- Ticker
- BBOT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857 702 0377
- Business address
- 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Helix Acquisition Corp. II
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-11 | Schmid John P. Former Director | Option exercise | +30,000 | 30,000 | ||
| 2025-08-11 | Schmid John P. Former Director | Option exercise · Class B ordinary shares | −30,000 | 0 | ||
| 2025-02-08 | Helix Holdings II LLC Director | Other disposition · Class B Ordinary Shares | −30,000 | 4,480,000 | ||
| 2025-02-08 | Chen Bihua CEO and Chairperson | Other disposition · Class B Ordinary Shares | −30,000 | 4,480,000 | ||
| 2024-02-13 | Chen Bihua CEO and Chairperson | Grant or award | +509,000 | $10.00 | $5.1M | 509,000 |
| 2024-02-13 | Chen Bihua CEO and Chairperson | Purchase | +69,360 | $10.00 | $694K | 69,360 |
| 2024-02-13 | Chen Bihua CEO and Chairperson | Purchase | +1,427,040 | $10.00 | $14.3M | 1,427,040 |
| 2024-02-13 | Chen Bihua CEO and Chairperson | Purchase | +903,600 | $10.00 | $9.0M | 903,600 |
| 2024-02-13 | Helix Holdings II LLC Director | Grant or award | +509,000 | $10.00 | $5.1M | 509,000 |
Page 4 of 4 · 69 trades